Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
What Clinical Trials Show In large obesity trials: Average weight loss is ~15% of starting body weight with semaglutide 2.4 mg Average weight loss is ~2022% of starting body weight with tirzepatide 15 mg The majority of weight loss occurs within the first year of treatment Plateaus are common after significant weight reduction Some people lose more, some less but a flattening of the weight-loss curve is expected , especially after meaningful progress has already occurred
NEJM , Jastreboff, Ania M., et al
Proceedings of the National Academy of Sciences of the United States of America, 76 (12), 63196322
Early data suggest retatrutide might provide more significant weight loss than its competitors
Today, many non-diabetic patients take GLP-1s to support weight loss , metabolic health, and insulin sensitivity
b Estimated using an ANCOVA based on data irrespectively of discontinuation of trial product or initiation of rescue medication adjusted for baseline value and region
US$ 24.01
US$ 27.69
US$ 26.67
US$ 24.42
US$ 20.28
